

ENSAYOS CLÍNICOS TUMORES DIGESTIVO

- COLORRECTAL

BNT 122-01

“A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection.”

<https://clinicaltrials.gov/ct2/show/NCT04486378>

MOUNTAINEER-03/SGNTUC-029

“An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer”

<https://classic.clinicaltrials.gov/ct2/show/NCT05253651>

TTD-21-02 (CEBBRA)

“Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF V600E mutated MSS initially resectable or potentially resectable advanced colorectal cancer”.

<https://classic.clinicaltrials.gov/ct2/show/NCT06207656>

219606-AZUR2

“A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer”

<https://clinicaltrials.gov/study/NCT05855200>

- GÁSTRICO

D7986C00001- GEMINI

“Novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma”

<https://clinicaltrials.gov/study/NCT05702229>

- ESÓGAFO

MK7902-014

"A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma"

<https://clinicaltrials.gov/ct2/show/NCT04949256>

- VIA BILIAR

TAS-120-205

"Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements"

<https://clinicaltrials.gov/study/NCT05727176>

TT420C2308

"A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with FGFR-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)"

<https://clinicaltrials.gov/study/NCT05948475>

ARTEMIDE - Biliary01

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent

<https://clinicaltrials.gov/study/NCT06109779?term=2023-506054-20-00&rank=1>

- PÁNCREAS

TRIPP-FFX

"An open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 (OncoSil™) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma"

<https://clinicaltrials.gov/ct2/show/NCT05466799>

EF-39 PANOVA-4

“EF-39: Pilot, single arm study of Tumor Treating Fields (TTFields, 150kHz) concomitant with atezolizumab, gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC)”

<https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-003157-55/ES>

- HEPATOCARCINOMA

M24-052

“A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment – LIVIGNO-2”

<https://clinicaltrials.gov/study/NCT05822752?tab=history&a=22>

NEUROENDOCRINO

COMPOSE

“Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)”

<https://classic.clinicaltrials.gov/ct2/show/NCT04919226>

TROMBOSIS

ANT-007 (ASTER)

“A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE”

<https://clinicaltrials.gov/ct2/show/NCT05171049>

ANT-008 (MAGNOLIA)

“A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE”

<https://clinicaltrials.gov/ct2/show/NCT05171075>